Alzheimer drug shows modest promise

BOSTON — Combined results from two studies of an experimental Alzheimer’s drug suggest it might modestly slow mental decline, especially in patients with mild disease.

Taken separately, the studies on the drug — Eli Lilly &Co.’s solanezumab — missed their main goals of significantly slowing the mind-robbing disease or improving activities of daily living. But pooled results found 34 percent less mental decline in mild Alzheimer’s patients compared to those on a fake treatment for 18 months.

Doctors called the results encouraging although probably not good enough to win approval of the drug now, without another study to confirm there is a benefit. Investors were more enthused, driving Lilly’s stock up about 5 percent on Monday and about 19 percent since August, when the company described the results in general terms.

Detailed results were revealed for the first time Monday at an American Neurological Association conference in Boston.

“It’s certainly not the home run we all wanted, but we’re very encouraged by these results,” said Maria Carillo, chief science officer for the Alzheimer’s Association, which had no role in the research.

Dr. Stephen Salloway, an Alzheimer’s expert at Brown University, agreed.

“It’s exciting to see that there may be clinical benefit,” he said, but it is modest and may not make a difference in how well patients live — what matters most to them and their families, he said.

About 35 million people worldwide have dementia, and Alzheimer’s is the most common type. In the U.S., about 5 million have Alzheimer’s. Current medicines such as Aricept and Namenda just temporarily ease symptoms. There is no known cure.

Solanezumab (sol-ah-NAYZ-uh-mab) is one of three drugs in late-stage testing that seek to alter the course of the disease. Results on one drug were disappointing, and results of the other won’t be ready until early next year.

Solanezumab aims to bind to and help clear the sticky deposits that clog patients’ brains. The two studies each had about 1,000 patients, about two-thirds with mild disease and one-third with moderately severe Alzheimer’s, in 16 countries. Their average age was 75.

The main measures were two tests — one reflecting language, memory and thinking and the other, ability to perform daily activities such as eating and grooming. The combined results on the mild disease patients showed a nearly 2-point difference in the roughly 90-point score on thinking abilities. Previous studies suggest that a change of 3 to 4 on the score is needed to show a clinical benefit, like an improvement in how well patients can take care of themselves.

“It’s a small difference,” Dr. Rachelle Doody of Baylor College of Medicine said of the drug’s effect. She heads a nationwide research network funded by the National Institute on Aging that did an independent analysis of Lilly’s results on the studies and presented them Monday at the conference.

Still, “you slow the decline” with the drug, she said.

Independent experts cautioned that the improvement was small, and needs to be verified in another study.

“I hate to get too enthusiastic … there’s a flicker of a signal” of benefit, but less than what some other once-promising treatments showed, said Dr. Sam Gandy, head of Alzheimer’s disease research at Mount Sinai School of Medicine in New York.

Dr. Ronald Petersen, director of Alzheimer’s research at the Mayo Clinic, called the drug’s effect “subtle” and said it may mean just that “somebody remembers one extra word out of a 15-word list” without any real improvement in how well they live.

The drug, if ever approved, is likely to be expensive, and that means “we need more evidence” of its benefit to justify its use, Petersen said.

Encouragingly, solanezumab had few side effects. About 1 percent of people on the drug had some chest pain from reduced blood flow to the heart. There were few cases of worrisome brain swelling and small bleeding in the brain, an effect that caused concern with another experimental Alzheimer’s drug, bapineuzumab by Pfizer Inc. and Johnson &Johnson’s Janssen Alzheimer Immunotherapy unit.

That drug failed to help patients in two late-stage studies announced last month, but did show signs of hitting its target and clearing deposits from the brain.

The Lilly drug seems to be safer, and that is an advantage, said Dr. Norman Relkin, head of a memory disorders program at New York-Presbyterian Hospital/Weill Cornell Medical Center.

“There is some cause for encouragement here. It’s not the magnitude we’d like to see” but certainly warrants further studies on the drug, he said.

Relkin heads testing of the third drug in late-stage development — Gammagard, by Baxter International Inc. Results are expected early next year.

Meanwhile, Dr. Eric Siemers, senior medical director for Lilly, said the company will discuss its results and next steps with the Food and Drug Administration.

Lilly shares closed up $2.55, or 5.3 percent, to $50.78. During the day they peaked at $50.94, their highest price since April 2008. (This is also their highest closing price since that month.) The shares are up 19.8 percent since August 24.

———

Online:

Alzheimer’s info: http://www.alzheimers.gov

Alzheimer’s Association: http://www.alz.org

———

Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP

Talk to us

> Give us your news tips.

> Send us a letter to the editor.

> More Herald contact information.

More in Local News

Olivia Vanni / The Herald 
The Mukilteo Lighthouse. Built in 1906, it’s one of the most iconic landmarks in Snohomish County.
The Mukilteo Lighthouse. Built in 1906, it’s one of the most iconic landmarks in Snohomish County. (Olivia Vanni / The Herald)
Mukilteo mayor vetoes council-approved sales tax

The tax would have helped pay for transportation infrastructure, but was also set to give Mukilteo the highest sales tax rate in the state.

Marysville Mayor Jon Nehring gives the state of the city address at the Marysville Civic Center on Wednesday, Jan. 31, 2024, in Marysville, Washington. (Ryan Berry / The Herald)
Marysville council approves interim middle housing law

The council passed the regulations to prevent a state model code from taking effect by default. It expects to approve final rules by October.

x
State audit takes issue with Edmonds COVID grant monitoring

The audit report covered 2023 and is the third since 2020 that found similar issues with COVID-19 recovery grant documentation.

Bothell
Bothell man pleads guilty to sexual abuse of Marysville middle schoolers

The man allegedly sexually assaulted three students in exchange for vapes and edibles in 2022. His sentencing is set for Aug. 29.

Larsen talks proposed Medicaid cuts during Compass Health stop in Everett

Compass Health plans to open its new behavioral health center in August. Nearly all of the nonprofit’s patients rely on Medicaid.

Snohomish County Health Department Director Dennis Worsham on Tuesday, June 11, 2024 in Everett, Washington. (Olivia Vanni / The Herald)
Snohomish County Health Department director tapped as WA health secretary

Dennis Worsham became the first director of the county health department in January 2023. His last day will be July 3.

Edmonds Police Chief Loi Dawkins speaks after the city council approved her appointment on Tuesday, July 8, 2025 in Edmonds, Washington. (Olivia Vanni / The Herald)
Edmonds City Council confirms new police chief

Assistant Chief Loi Dawkins will begin in the role Aug. 1. She has more than 23 years of law enforcement experience, including three years in Edmonds.

Community members gather for the dedication of the Oso Landslide Memorial following the ten-year remembrance of the slide on Friday, March 22, 2024, at the Oso Landslide Memorial in Oso, Washington. (Ryan Berry / The Herald)
The Daily Herald garners 6 awards from regional journalism competition

The awards recognize the best in journalism from media outlets across Alaska, Idaho, Montana, Oregon and Washington.

The Edmonds City Council discuss the levy during a city council meeting on Tuesday, July 8, 2025 in Edmonds, Washington. (Olivia Vanni / The Herald)
Edmonds votes to place levy lid lift on the ballot

By a vote of 5-2, the council decided to put the $14.5 million property tax levy lid lift to voters in November.

A trash hauler from Republic Services. (Provided photo)
Growing Teamsters strike disrupts garbage pickup in Snohomish County

Republic Services customers in Edmonds, Monroe and Snohomish were told an “out-of-market labor disruption” affected their garbage pickup on Wednesday.

Lily Lamoureux stacks Weebly Funko toys in preparation for Funko Friday at Funko Field in Everett on July 12, 2019.  Kevin Clark / The Herald)
Everett-based Funko ousts its CEO after 14 months

The company, known for its toy figures based on pop culture, named Michael Lunsford as its interim CEO.

‘Courageous’ teen dives into Silver Lake to rescue 11-year-old

Gauge Bryant, 13, brought the child to the surface. The 11-year-old is in stable but critical condition, authorities said.

Support local journalism

If you value local news, make a gift now to support the trusted journalism you get in The Daily Herald. Donations processed in this system are not tax deductible.